Merck Asks EU Regulator to Authorize Pill That Treats COVID-19

Merck Asks EU Regulator to Authorize Pill That Treats COVID-19
An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co. Inc. and Ridgeback Biotherapeutics LP, is seen in this undated photo obtained by Reuters on May 17, 2021. Merck & Co. Inc./Handout via Reuters
The Associated Press
Updated:

AMSTERDAM—The pharmaceutical company Merck says it has asked the European Medicines Agency to authorize its COVID-19 antiviral treatment, the first pill that has been shown to treat the disease.

In a statement on Monday, Merck said the EU drug regulator had started an expedited licensing process for molnupiravir. If given the green light, it would be the first treatment for COVID-19 that does not need to be administered through needles or intravenous infusions.